EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Quality and in vitro bioequivalence evaluation of different brands of amoxicillin + clavulanic acid (500 + 62.5) mg tablets distributed in Burkina Faso

Josias Yaméogo, Mathias Zombré, Hermine Zimé Diawara, Charles Sombié, W. Bertrand Goumbri, Wendpouiré Zoungrana Somé, Aïssata Sanfo Diasso, Elie Kabré, Rasmané Semdé

Journal Africain de Technologie Pharmaceutique et Biopharmacie (JATPB) · 2023

DOI: 10.57220/jatpb.v2i2.49 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal Africain de Technologie Pharmaceutique et Biopharmacie (JATPB), 2023. Verfasst von Josias Yaméogo und 8 weiteren Autor:innen. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

In a previous study, we reported the evaluation of the physicochemical quality and in vitro bioequivalence of different brands of amoxicillin capsules 500 mg marketed in Burkina Faso. As our goal was to document the quality and biopharmaceutical performance of essential antibiotics marketed in resource-limited countries, we investigated here, the interchangeability with the originator of five brands of amoxicillin + clavulanic acid (500mg+62.5mg) tablets distributed in Burkina Faso. The physicochemical quality of the different brands was first verified according to the USP monograph. The comparative evaluation of the in vitro dissolution profiles was performed in three different pH environments (1.2 - 4.5 - 6.8) using statistical calculations of the difference (f1) and similarity (f2) factors. All brands of amoxicillin + clavulanic acid (500mg+62.5mg) tablets, including the originator, met USP specifications for weight uniformity, identification, content and dissolution of active ingredients. However, the similarity and difference factor values showed that two generic brands (B and E) did not have similar amoxicillin dissolution profiles to the comparator product in pH 4.5 media (f1 = 23,54 and 17.02; f2=35.96 and 46.90, respectively). Therefore, these two products cannot be used interchangeably with the originator. The other three generic brands were similar to the originator and can therefore probably be used interchangeably.

Zitieren

APA

Yaméogo, J., Zombré, M., Diawara, H. Z., Sombié, C., Goumbri, W. B., Somé, W. Z., Diasso, A. S., Kabré, E., & Semdé, R. (2023). Quality and in vitro bioequivalence evaluation of different brands of amoxicillin + clavulanic acid (500 + 62.5) mg tablets distributed in Burkina Faso. Journal Africain de Technologie Pharmaceutique et Biopharmacie (JATPB). https://doi.org/10.57220/jatpb.v2i2.49

Vancouver

Yaméogo J, Zombré M, Diawara HZ, Sombié C, Goumbri WB, Somé WZ, et al. Quality and in vitro bioequivalence evaluation of different brands of amoxicillin + clavulanic acid (500 + 62.5) mg tablets distributed in Burkina Faso. Journal Africain de Technologie Pharmaceutique et Biopharmacie (JATPB). 2023. doi:10.57220/jatpb.v2i2.49

BibTeX
@article{Yamogo2023,
  author = {Yaméogo, Josias and Zombré, Mathias and Diawara, Hermine Zimé and Sombié, Charles and Goumbri, W. Bertrand and Somé, Wendpouiré Zoungrana and Diasso, Aïssata Sanfo and Kabré, Elie and Semdé, Rasmané},
  title = {Quality and in vitro bioequivalence evaluation of different brands of amoxicillin + clavulanic acid (500 + 62.5) mg tablets distributed in Burkina Faso},
  journal = {Journal Africain de Technologie Pharmaceutique et Biopharmacie (JATPB)},
  year = {2023},
  doi = {10.57220/jatpb.v2i2.49}
}
Kostenlos starten →